Quent Capital LLC Sells 22 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Quent Capital LLC decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.2% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 399 shares of the biopharmaceutical company’s stock after selling 22 shares during the quarter. Quent Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $253,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of REGN. Brighton Jones LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after buying an additional 686 shares during the period. Blue Trust Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 39.8% during the 4th quarter. Blue Trust Inc. now owns 724 shares of the biopharmaceutical company’s stock worth $516,000 after buying an additional 206 shares during the period. First Affirmative Financial Network boosted its holdings in shares of Regeneron Pharmaceuticals by 28.6% during the 4th quarter. First Affirmative Financial Network now owns 288 shares of the biopharmaceutical company’s stock worth $205,000 after buying an additional 64 shares during the period. Mediolanum International Funds Ltd boosted its holdings in shares of Regeneron Pharmaceuticals by 5.3% during the 4th quarter. Mediolanum International Funds Ltd now owns 4,449 shares of the biopharmaceutical company’s stock worth $3,118,000 after buying an additional 224 shares during the period. Finally, AA Financial Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 16.1% during the 4th quarter. AA Financial Advisors LLC now owns 448 shares of the biopharmaceutical company’s stock worth $319,000 after buying an additional 62 shares during the period. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on REGN shares. Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. TD Cowen decreased their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th. Bernstein Bank decreased their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Robert W. Baird decreased their target price on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating on the stock in a research report on Friday, April 25th. Finally, Cantor Fitzgerald initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $695.00 target price on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $874.56.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $493.24 on Friday. The company has a market cap of $53.25 billion, a price-to-earnings ratio of 12.89, a PEG ratio of 2.34 and a beta of 0.43. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm has a 50 day simple moving average of $584.25 and a 200 day simple moving average of $667.42. Regeneron Pharmaceuticals, Inc. has a one year low of $485.00 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same period in the previous year, the company earned $9.55 EPS. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.71%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.